{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:45:09Z","timestamp":1793295909236,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11523-022-00876-z","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T13:05:42Z","timestamp":1650546342000},"page":"223-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4077-0491","authenticated-orcid":false,"given":"Thomas D.","family":"McLean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Duchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Di Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"876_CR1","volume-title":"WHO classification of tumours of soft tissue and bone. World Health Organization classification of tumours","author":"CDM Fletcher","year":"2013","unstructured":"Fletcher CDM. WHO classification of tumours of soft tissue and bone. World Health Organization classification of tumours. Geneva: International Agency for Research on Cancer; 2013."},{"issue":"1","key":"876_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ijc.25664","volume":"129","author":"MH Nieuwenhuis","year":"2011","unstructured":"Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129(1):256\u201361. https:\/\/doi.org\/10.1002\/ijc.25664.","journal-title":"Int J Cancer"},{"issue":"9","key":"876_CR3","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1245\/s10434-015-4632-y","volume":"22","author":"DL van Broekhoven","year":"2015","unstructured":"van Broekhoven DL, Gr\u00fcnhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817\u201323. https:\/\/doi.org\/10.1245\/s10434-015-4632-y.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"876_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/gut.35.3.377","volume":"35","author":"AK Gurbuz","year":"1994","unstructured":"Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV, et al. Desmoid tumours in familial adenomatous polyposis. Gut. 1994;35(3):377\u201381. https:\/\/doi.org\/10.1136\/gut.35.3.377.","journal-title":"Gut"},{"issue":"6","key":"876_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/jso.24699","volume":"116","author":"L Koskenvuo","year":"2017","unstructured":"Koskenvuo L, Ristim\u00e4ki A, Lepist\u00f6 A. Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol. 2017;116(6):716\u201321. https:\/\/doi.org\/10.1002\/jso.24699.","journal-title":"J Surg Oncol"},{"issue":"9","key":"876_CR6","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1245\/s10434-009-0586-2","volume":"16","author":"M Fiore","year":"2009","unstructured":"Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le P\u00e9choux C, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587\u201393. https:\/\/doi.org\/10.1245\/s10434-009-0586-2.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"876_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.soc.2016.05.010","volume":"25","author":"M Fiore","year":"2016","unstructured":"Fiore M, MacNeill A, Gronchi A, Colombo C. Desmoid-type fibromatosis: evolving treatment standards. Surg Oncol Clin N Am. 2016;25(4):803\u201326. https:\/\/doi.org\/10.1016\/j.soc.2016.05.010.","journal-title":"Surg Oncol Clin N Am"},{"issue":"5","key":"876_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11864-017-0474-0","volume":"18","author":"J Mart\u00ednez Trufero","year":"2017","unstructured":"Mart\u00ednez Trufero J, Pajares Bernad I, Torres Ram\u00f3n I, Hernando Cubero J, Pazo CR. Desmoid-type fibromatosis: who, when, and how to treat. Curr Treat Options Oncol. 2017;18(5):29. https:\/\/doi.org\/10.1007\/s11864-017-0474-0.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"876_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2014.11.005","volume":"51","author":"B Kasper","year":"2015","unstructured":"Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients\u2019 and professionals\u2019 expertise: a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer\/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015;51(2):127\u201336. https:\/\/doi.org\/10.1016\/j.ejca.2014.11.005.","journal-title":"Eur J Cancer"},{"key":"876_CR10","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3389\/fonc.2019.01248","volume":"9","author":"Y Lecarpentier","year":"2019","unstructured":"Lecarpentier Y, Schussler O, H\u00e9bert J-L, Vall\u00e9e A. Multiple targets of the canonical WNT\/\u03b2-catenin signaling in cancers. Front Oncol. 2019;9:1248. https:\/\/doi.org\/10.3389\/fonc.2019.01248.","journal-title":"Front Oncol"},{"issue":"3","key":"876_CR11","first-page":"131","volume":"38","author":"JJ Olsen","year":"2017","unstructured":"Olsen JJ, Pohl S, Deshmukh A, Visweswaran M, Ward NC, Arfuso F, et al. The role of Wnt signalling in angiogenesis. Clin Biochem Rev. 2017;38(3):131\u201342.","journal-title":"Clin Biochem Rev"},{"issue":"5","key":"876_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1101\/gad.14.5.585","volume":"14","author":"L Xu","year":"2000","unstructured":"Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev. 2000;14(5):585\u201395.","journal-title":"Genes Dev"},{"issue":"1","key":"876_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald BT, Tamai K, He X. Wnt\/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9\u201326. https:\/\/doi.org\/10.1016\/j.devcel.2009.06.016.","journal-title":"Dev Cell"},{"key":"876_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40591-015-0038-2","volume":"3","author":"MV Enzo","year":"2015","unstructured":"Enzo MV, Rastrelli M, Rossi CR, Hladnik U, Segat D. The Wnt\/\u03b2-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target. Mol Cell Ther. 2015;3:1. https:\/\/doi.org\/10.1186\/s40591-015-0038-2.","journal-title":"Mol Cell Ther."},{"issue":"10","key":"876_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/gcc.22272","volume":"54","author":"AM Crago","year":"2015","unstructured":"Crago AM, Chmielecki J, Rosenberg M, O\u2019Connor R, Byrne C, Wilder FG, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54(10):606\u201315. https:\/\/doi.org\/10.1002\/gcc.22272.","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"876_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00428-015-1765-0","volume":"467","author":"SJ Aitken","year":"2015","unstructured":"Aitken SJ, Presneau N, Kalimuthu S, Dileo P, Berisha F, Tirabosco R, et al. Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Arch. 2015;467(2):203\u201310. https:\/\/doi.org\/10.1007\/s00428-015-1765-0.","journal-title":"Virchows Arch"},{"issue":"1","key":"876_CR17","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1038\/s41598-020-60237-6","volume":"10","author":"M Trautmann","year":"2020","unstructured":"Trautmann M, Rehkamper J, Gevensleben H, Becker J, Wardelmann E, Hartmann W, et al. Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis: a systematic analysis of 204 cases. Sci. 2020;10(1):3368. https:\/\/doi.org\/10.1038\/s41598-020-60237-6.","journal-title":"Sci"},{"issue":"47","key":"876_CR18","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.1038\/sj.onc.1203041","volume":"18","author":"S Tejpar","year":"1999","unstructured":"Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18(47):6615\u201320. https:\/\/doi.org\/10.1038\/sj.onc.1203041.","journal-title":"Oncogene"},{"key":"876_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2016.02.008","volume":"58","author":"N Penel","year":"2016","unstructured":"Penel N, Coindre JM, Bonvalot S, Italiano A, Neuville A, Le Cesne A, et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France. Eur J Cancer. 2016;58:90\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.008.","journal-title":"Eur J Cancer"},{"key":"876_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2017.06.017","volume":"83","author":"N Penel","year":"2017","unstructured":"Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.017.","journal-title":"Eur J Cancer"},{"key":"876_CR21","doi-asserted-by":"publisher","unstructured":"Desmoid Tumor Working G. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96\u2013107. doi: https:\/\/doi.org\/10.1016\/j.ejca.2019.11.013.","DOI":"10.1016\/j.ejca.2019.11.013"},{"issue":"4","key":"876_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence: study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407\u201315. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.017.","journal-title":"J Clin Epidemiol"},{"key":"876_CR23","unstructured":"JBI. Checklist for case series. 2020. https:\/\/jbi.global\/critical-appraisal-tools. Accessed 27 Mar 2022."},{"issue":"3","key":"876_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1365-2559.2011.03945.x","volume":"59","author":"H Matono","year":"2011","unstructured":"Matono H, Tamiya S, Yokoyama R, Saito T, Iwamoto Y, Tsuneyoshi M, et al. Abnormalities of the Wnt\/beta-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between beta-catenin widespread nuclear expression and VEGF overexpression. Histopathology. 2011;59(3):368\u201375. https:\/\/doi.org\/10.1111\/j.1365-2559.2011.03945.x.","journal-title":"Histopathology"},{"issue":"5","key":"876_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.prp.2008.11.002","volume":"205","author":"T Ferenc","year":"2009","unstructured":"Ferenc T, Wronski JW, Kopczynski J, Kulig A, Sidor M, Stalinska L, et al. Analysis of APC, alpha-, beta-catenins, and N-cadherin protein expression in aggressive fibromatosis (desmoid tumor). Pathol Res Pract. 2009;205(5):311\u201324. https:\/\/doi.org\/10.1016\/j.prp.2008.11.002.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"876_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/00313020701329823","volume":"39","author":"Y Jilong","year":"2007","unstructured":"Jilong Y, Jian W, Xiaoyan Z, Xiaoqiu L, Xiongzeng Z. Analysis of APC\/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis. Pathology. 2007;39(3):319\u201325. https:\/\/doi.org\/10.1080\/00313020701329823.","journal-title":"Pathology"},{"issue":"2","key":"876_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/path.942","volume":"195","author":"T Saito","year":"2001","unstructured":"Saito T, Oda Y, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, et al. beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. J Pathol. 2001;195(2):222\u20138. https:\/\/doi.org\/10.1002\/path.942.","journal-title":"J Pathol"},{"issue":"4","key":"876_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250619","volume":"16","author":"J An","year":"2021","unstructured":"An J, Woo HY, Lee Y, Kim HS, Jeong J, Kim SK. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by beta-catenin immunohistochemical staining and CTNNB1 mutation analysis. PLoS ONE. 2021;16(4): e0250619. https:\/\/doi.org\/10.1371\/journal.pone.0250619.","journal-title":"PLoS ONE"},{"issue":"12","key":"876_CR29","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.humpath.2008.05.005","volume":"39","author":"H Matono","year":"2008","unstructured":"Matono H, Oda Y, Nakamori M, Tamiya S, Yamamoto H, Yokoyama R, et al. Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors. Hum Pathol. 2008;39(12):1802\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2008.05.005.","journal-title":"Hum Pathol"},{"issue":"4","key":"876_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2559.2007.02619.x","volume":"50","author":"C Gebert","year":"2007","unstructured":"Gebert C, Hardes J, Kersting C, August C, Supper H, Winkelmann W, et al. Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology. 2007;50(4):491\u20137. https:\/\/doi.org\/10.1111\/j.1365-2559.2007.02619.x.","journal-title":"Histopathology"},{"issue":"1","key":"876_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/labinvest.3780399","volume":"82","author":"T Saito","year":"2002","unstructured":"Saito T, Oda Y, Kawaguchi K, Tanaka K, Matsuda S, Tamiya S, et al. Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan polymerase chain reaction. Lab Investig. 2002;82(1):97\u2013103.","journal-title":"Lab Investig"},{"issue":"12","key":"876_CR32","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/cas.12037","volume":"103","author":"NA Mignemi","year":"2012","unstructured":"Mignemi NA, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, et al. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-beta, COX2 and sex steroid receptors. Cancer Sci. 2012;103(12):2173\u201380. https:\/\/doi.org\/10.1111\/cas.12037.","journal-title":"Cancer Sci"},{"issue":"8","key":"876_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/PAI.0000000000000340","volume":"25","author":"S Varghese","year":"2017","unstructured":"Varghese S, Braggio DA, Gillespie J, Toland AE, Pollock R, Mayerson J, et al. TGF-beta and CTGF are mitogenic output mediators of Wnt\/beta-catenin signaling in desmoid fibromatosis. Appl Immunohistochem Molecul Morphol. 2017;25(8):559\u201365. https:\/\/doi.org\/10.1097\/PAI.0000000000000340.","journal-title":"Appl Immunohistochem Molecul Morphol."},{"issue":"8","key":"876_CR34","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrm3629","volume":"14","author":"C Bertoli","year":"2013","unstructured":"Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013;14(8):518\u201328. https:\/\/doi.org\/10.1038\/nrm3629.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"876_CR35","doi-asserted-by":"publisher","first-page":"18693","DOI":"10.1038\/s41598-019-54917-1","volume":"9","author":"L Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez L, Bretones G, Molina E, Arechaga I, Symonds C, Acosta JC, et al. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27. Sci Rep. 2019;9(1):18693. https:\/\/doi.org\/10.1038\/s41598-019-54917-1.","journal-title":"Sci Rep"},{"issue":"7","key":"876_CR36","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/jso.25407","volume":"119","author":"K Santti","year":"2019","unstructured":"Santti K, Ihalainen H, Ronty M, Karlsson C, Haglund C, Sampo M, et al. Estrogen receptor beta expression correlates with proliferation in desmoid tumors. J Surg Oncol. 2019;119(7):873\u20139. https:\/\/doi.org\/10.1002\/jso.25407.","journal-title":"J Surg Oncol"},{"issue":"7","key":"876_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s004320000225","volume":"127","author":"W Dempke","year":"2001","unstructured":"Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001;127(7):411\u20137. https:\/\/doi.org\/10.1007\/s004320000225.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"876_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bbcan.2005.08.006","volume":"1765","author":"JK Kundu","year":"2006","unstructured":"Kundu JK, Choi KY, Surh YJ. beta-Catenin-mediated signaling: a novel molecular target for chemoprevention with anti-inflammatory substances. Biochim Biophys Acta. 2006;1765(1):14\u201324. https:\/\/doi.org\/10.1016\/j.bbcan.2005.08.006.","journal-title":"Biochim Biophys Acta"},{"issue":"17","key":"876_CR39","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-07-0336","volume":"13","author":"S Signoroni","year":"2007","unstructured":"Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res. 2007;13(17):5034\u201340.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"876_CR40","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.humpath.2011.12.021","volume":"43","author":"JM Cates","year":"2012","unstructured":"Cates JM, Black JO, Itani DM, Fasig JH, Keedy VL, Hande KR, et al. Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases. Hum Pathol. 2012;43(10):1711\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2011.12.021.","journal-title":"Hum Pathol"},{"issue":"10","key":"876_CR41","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9 J. TGF\u03b2 signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616\u201330. https:\/\/doi.org\/10.1038\/nrm3434.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"876_CR42","first-page":"25","volume":"4","author":"GA Santos","year":"2010","unstructured":"Santos GA, Cunha IW, Rocha RM, Mello CA, Guimaraes GC, Fregnani JH, et al. Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. Biosci Trends. 2010;4(1):25\u201330.","journal-title":"Biosci Trends"},{"issue":"11","key":"876_CR43","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/jcp.2005.026278","volume":"58","author":"A Leithner","year":"2005","unstructured":"Leithner A, Gapp M, Radl R, Pascher A, Krippl P, Leithner K, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol. 2005;58(11):1152\u20136.","journal-title":"J Clin Pathol"},{"issue":"1","key":"876_CR44","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cncr.21553","volume":"106","author":"AT Deyrup","year":"2006","unstructured":"Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer. 2006;106(1):208\u201313. https:\/\/doi.org\/10.1002\/cncr.21553.","journal-title":"Cancer"},{"issue":"3","key":"876_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1620\/tjem.210.189","volume":"210","author":"M Ishizuka","year":"2006","unstructured":"Ishizuka M, Hatori M, Dohi O, Suzuki T, Miki Y, Tazawa C, et al. Expression profiles of sex steroid receptors in desmoid tumors. Tohoku J Exp Med. 2006;210(3):189\u201398. https:\/\/doi.org\/10.1620\/tjem.210.189.","journal-title":"Tohoku J Exp Med"},{"key":"876_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2019.151442","volume":"44","author":"K Brautigam","year":"2020","unstructured":"Brautigam K, Lindner J, Budczies J, Pahl S, Kunitz A, Melcher I, et al. PARP-1 expression as a prognostic factor in desmoid-type fibromatosis. Ann Diagn Pathol. 2020;44: 151442. https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.151442.","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"876_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52\u201367. https:\/\/doi.org\/10.1016\/j.cell.2010.03.015.","journal-title":"Cell"},{"issue":"4","key":"876_CR48","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/path.2951","volume":"225","author":"C Colombo","year":"2011","unstructured":"Colombo C, Creighton CJ, Ghadimi MP, Bolshakov S, Warneke CL, Zhang Y, et al. Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target. J Pathol. 2011;225(4):574\u201382. https:\/\/doi.org\/10.1002\/path.2951.","journal-title":"J Pathol"},{"issue":"3","key":"876_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13577140120048601","volume":"5","author":"J Ahlen","year":"2001","unstructured":"Ahlen J, Enberg U, Larsson C, Larsson O, Frisk T, Brosjo O, et al. Malignant fibrous histiocytoma, aggressive fibromatosis and benign fibrous tumors wxpress mRNA for the metalloproteinase inducer EMMPRIN and the metalloproteinases MMP-2 and MT1-MMP. Sarcoma. 2001;5(3):143\u20139. https:\/\/doi.org\/10.1080\/13577140120048601.","journal-title":"Sarcoma"},{"issue":"1","key":"876_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cam4.160","volume":"3","author":"BS Misemer","year":"2014","unstructured":"Misemer BS, Skubitz APN, Carlos Manivel J, Schmechel SC, Cheng EY, Henriksen JC, et al. Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity. Cancer Med. 2014;3(1):81\u201390. https:\/\/doi.org\/10.1002\/cam4.160.","journal-title":"Cancer Med"},{"issue":"Suppl. 3","key":"876_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl. 3):4\u201310. https:\/\/doi.org\/10.1159\/000088478.","journal-title":"Oncology"},{"issue":"5","key":"876_CR52","first-page":"1913","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021;11(5):1913\u201335.","journal-title":"Am J Cancer Res"},{"issue":"53","key":"876_CR53","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1038\/sj.onc.1203015","volume":"18","author":"ND Lakin","year":"1999","unstructured":"Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene. 1999;18(53):7644\u201355. https:\/\/doi.org\/10.1038\/sj.onc.1203015.","journal-title":"Oncogene"},{"key":"876_CR54","doi-asserted-by":"publisher","unstructured":"Lipovka Y, Konhilas JP. The complex nature of oestrogen signalling in breast cancer: enemy or ally? 2016. Biosci Rep. https:\/\/doi.org\/10.1042\/bsr20160017.","DOI":"10.1042\/bsr20160017"},{"issue":"3","key":"876_CR55","first-page":"299","volume":"24","author":"L Stalinska","year":"2009","unstructured":"Stalinska L, Turant M, Tosik D, Sygut J, Kulig A, Kopczynski J, et al. Analysis of pRb, p16INK4A proteins and proliferating antigens: PCNA, Ki-67 and MCM5 expression in aggressive fibromatosis (desmoid tumor). Histol Histopathol. 2009;24(3):299\u2013308.","journal-title":"Histol Histopathol"},{"issue":"Pt 2","key":"876_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1042\/bst0360149","volume":"36","author":"WJ Nelson","year":"2008","unstructured":"Nelson WJ. Regulation of cell-cell adhesion by the cadherin-catenin complex. Biochem Soc Trans. 2008;36(Pt 2):149\u201355. https:\/\/doi.org\/10.1042\/bst0360149.","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"876_CR57","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985\u201399. https:\/\/doi.org\/10.1016\/j.cell.2017.05.016.","journal-title":"Cell"},{"key":"876_CR58","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fonc.2019.00397","volume":"9","author":"MJM Timbergen","year":"2019","unstructured":"Timbergen MJM, Smits R, Grunhagen DJ, Verhoef C, Sleijfer S, Wiemer EAC. Activated signaling pathways and targeted therapies in desmoid-type fibromatosis: a literature review. Front Oncol. 2019;9:397. https:\/\/doi.org\/10.3389\/fonc.2019.00397.","journal-title":"Front Oncol"},{"issue":"24","key":"876_CR59","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1158\/1078-0432.Ccr-17-2157","volume":"23","author":"A Jimeno","year":"2017","unstructured":"Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, et al. A first-in-Human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. Clin Cancer Res. 2017;23(24):7490\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2157.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"876_CR60","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/gut.2009.204719","volume":"60","author":"G Peignon","year":"2011","unstructured":"Peignon G, Durand A, Cacheux W, Ayrault O, Terris B, Laurent-Puig P, et al. Complex interplay between \u03b2-catenin signalling and Notch effectors in intestinal tumorigenesis. Gut. 2011;60(2):166\u201376. https:\/\/doi.org\/10.1136\/gut.2009.204719.","journal-title":"Gut"},{"issue":"15","key":"876_CR61","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1073\/pnas.0813221106","volume":"106","author":"V Rodilla","year":"2009","unstructured":"Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fern\u00e1ndez-Majada V, Grilli A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA. 2009;106(15):6315\u201320. https:\/\/doi.org\/10.1073\/pnas.0813221106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"876_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017957","volume":"6","author":"J Ungerb\u00e4ck","year":"2011","unstructured":"Ungerb\u00e4ck J, Elander N, Gr\u00fcnberg J, Sigvardsson M, S\u00f6derkvist P. The Notch-2 gene is regulated by Wnt signaling in cultured colorectal cancer cells. PLoS ONE. 2011;6(3): e17957. https:\/\/doi.org\/10.1371\/journal.pone.0017957.","journal-title":"PLoS ONE"},{"issue":"14","key":"876_CR63","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1200\/jco.2016.71.1994","volume":"35","author":"S Kummar","year":"2017","unstructured":"Kummar S, O\u2019Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E, et al. Clinical activity of the \u03b3-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). J Clin Oncol. 2017;35(14):1561\u20139. https:\/\/doi.org\/10.1200\/jco.2016.71.1994.","journal-title":"J Clin Oncol"},{"key":"876_CR64","unstructured":"SpringWorksTherapeutics. Nirogacestat for adults with desmoid tumor\/aggressive fibromatosis (DT\/AF) (DeFi). ClinicalTrials.gov. 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03785964?id=NCT03785964&draw=2&rank=1&load=cart. Accessed 27 Mar 2021."},{"issue":"20","key":"876_CR65","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1810527.","journal-title":"N Engl J Med"},{"issue":"11","key":"876_CR66","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1002\/cncr.11029","volume":"95","author":"J Mace","year":"2002","unstructured":"Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer. 2002;95(11):2373\u20139. https:\/\/doi.org\/10.1002\/cncr.11029.","journal-title":"Cancer"},{"issue":"3","key":"876_CR67","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1309\/ej3ry45qcypukqg4","volume":"119","author":"JL Hornick","year":"2003","unstructured":"Hornick JL, Fletcher CD. Validating immunohistochemical staining for KIT (CD117). Am J Clin Pathol. 2003;119(3):325\u20137. https:\/\/doi.org\/10.1309\/ej3ry45qcypukqg4.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"876_CR68","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","volume":"2","author":"F Broekman","year":"2011","unstructured":"Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: multi-targeted or single-targeted? World J Clin Oncol. 2011;2(2):80\u201393. https:\/\/doi.org\/10.5306\/wjco.v2.i2.80.","journal-title":"World J Clin Oncol."},{"issue":"2","key":"876_CR69","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdq341","volume":"22","author":"N Penel","year":"2011","unstructured":"Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC\/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22(2):452\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdq341.","journal-title":"Ann Oncol"},{"issue":"25","key":"876_CR70","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","volume":"379","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379(25):2417\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1805052.","journal-title":"N Engl J Med"},{"issue":"9","key":"876_CR71","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/s1470-2045(19)30276-1","volume":"20","author":"M Toulmonde","year":"2019","unstructured":"Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019;20(9):1263\u201372. https:\/\/doi.org\/10.1016\/s1470-2045(19)30276-1.","journal-title":"Lancet Oncol"},{"key":"876_CR72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.steroids.2014.06.012","volume":"90","author":"I Paterni","year":"2014","unstructured":"Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen receptors alpha (ER\u03b1) and beta (ER\u03b2): subtype-selective ligands and clinical potential. Steroids. 2014;90:13\u201329. https:\/\/doi.org\/10.1016\/j.steroids.2014.06.012.","journal-title":"Steroids"},{"issue":"5","key":"876_CR73","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1096\/fj.11-194779","volume":"26","author":"M Velders","year":"2012","unstructured":"Velders M, Schleipen B, Fritzemeier KH, Zierau O, Diel P. Selective estrogen receptor-\u03b2 activation stimulates skeletal muscle growth and regeneration. FASESB J. 2012;26(5):1909\u201320. https:\/\/doi.org\/10.1096\/fj.11-194779.","journal-title":"FASESB J."},{"issue":"1","key":"876_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40364-020-00223-2","volume":"8","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Liu X. The role of estrogen receptor beta in breast cancer. Biomark Res. 2020;8(1):39. https:\/\/doi.org\/10.1186\/s40364-020-00223-2.","journal-title":"Biomark Res."},{"issue":"12","key":"876_CR75","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1111\/j.1463-1318.2011.02758.x","volume":"13","author":"D Bocale","year":"2011","unstructured":"Bocale D, Rotelli MT, Cavallini A, Altomare DF. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis. 2011;13(12):e388\u201395. https:\/\/doi.org\/10.1111\/j.1463-1318.2011.02758.x.","journal-title":"Colorectal Dis"},{"issue":"7","key":"876_CR76","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/pbc.24457","volume":"60","author":"SX Skapek","year":"2013","unstructured":"Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children\u2019s Oncology Group (COG) phase II study. Pediatr Blood Cancer. 2013;60(7):1108\u201312. https:\/\/doi.org\/10.1002\/pbc.24457.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"876_CR77","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/sj.bjc.6601661","volume":"90","author":"H Denys","year":"2004","unstructured":"Denys H, De Wever O, Nusgens B, Kong Y, Sciot R, Le AT, et al. Invasion and MMP expression profile in desmoid tumours. Br J Cancer. 2004;90(7):1443\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6601661.","journal-title":"Br J Cancer"},{"issue":"16","key":"876_CR78","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/0008-5472.Can-03-3112","volume":"64","author":"Y Kong","year":"2004","unstructured":"Kong Y, Poon R, Nadesan P, Di Muccio T, Fodde R, Khokha R, et al. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. Cancer Res. 2004;64(16):5795\u2013803. https:\/\/doi.org\/10.1158\/0008-5472.Can-03-3112.","journal-title":"Cancer Res"},{"issue":"6","key":"876_CR79","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1535-7163.Mct-17-0646","volume":"17","author":"A Winer","year":"2018","unstructured":"Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018;17(6):1147\u201355. https:\/\/doi.org\/10.1158\/1535-7163.Mct-17-0646.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"876_CR80","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/cam4.669","volume":"5","author":"C Meazza","year":"2016","unstructured":"Meazza C, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L, et al. AKT1 and BRAF mutations in pediatric aggressive fibromatosis. Cancer Med. 2016;5(6):1204\u201313. https:\/\/doi.org\/10.1002\/cam4.669.","journal-title":"Cancer Med"},{"issue":"16","key":"876_CR81","doi-asserted-by":"publisher","first-page":"8233","DOI":"10.1158\/0008-5472.Can-06-1209","volume":"66","author":"SC Martinico","year":"2006","unstructured":"Martinico SC, Jezzard S, Sturt NJ, Michils G, Tejpar S, Phillips RK, et al. Assessment of endostatin gene therapy for familial adenomatous polyposis-related desmoid tumors. Cancer Res. 2006;66(16):8233\u201340. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-1209.","journal-title":"Cancer Res"},{"key":"876_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Meth. 2020. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Meth."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-022-00876-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T09:26:10Z","timestamp":1658136370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-022-00876-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1007\/s11523-022-00876-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"15 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TDM completed the literature search, wrote the first draft of the manuscript and critically revised the manuscript. SD and CDB contributed ideas and content and critically revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}